SAGE Therapeutics Inc (NASDAQ:SAGE) – Research analysts at Leerink Swann issued their FY2022 earnings per share (EPS) estimates for SAGE Therapeutics in a research report issued on Monday, November 12th, Zacks Investment Research reports. Leerink Swann analyst M. Goodman expects that the biopharmaceutical company will post earnings per share of ($4.50) for the year. Leerink Swann has a “Underperform” rating and a $80.00 price objective on the stock.

A number of other research firms have also commented on SAGE. Oppenheimer set a $170.00 price objective on shares of SAGE Therapeutics and gave the company a “buy” rating in a research note on Tuesday, November 20th. BidaskClub raised shares of SAGE Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Tuesday. LADENBURG THALM/SH SH set a $235.00 price objective on shares of SAGE Therapeutics and gave the company a “buy” rating in a research note on Wednesday, October 31st. JPMorgan Chase & Co. set a $205.00 price objective on shares of SAGE Therapeutics and gave the company a “buy” rating in a research note on Tuesday, November 6th. Finally, Cowen reaffirmed a “buy” rating and issued a $207.00 price objective on shares of SAGE Therapeutics in a research note on Thursday, November 1st. Two research analysts have rated the stock with a sell rating, eleven have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $204.08.

Shares of NASDAQ:SAGE traded down $3.20 during trading on Wednesday, reaching $102.68. The stock had a trading volume of 306,697 shares, compared to its average volume of 352,874. SAGE Therapeutics has a 52 week low of $100.75 and a 52 week high of $195.97. The firm has a market cap of $4.96 billion, a P/E ratio of -14.48 and a beta of 2.72.

SAGE Therapeutics (NASDAQ:SAGE) last posted its quarterly earnings data on Tuesday, November 6th. The biopharmaceutical company reported ($2.63) EPS for the quarter, missing the Zacks’ consensus estimate of ($2.41) by ($0.22). During the same quarter in the prior year, the company earned ($1.97) EPS.

Several institutional investors have recently added to or reduced their stakes in SAGE. Dimensional Fund Advisors LP lifted its position in shares of SAGE Therapeutics by 58.1% during the 1st quarter. Dimensional Fund Advisors LP now owns 46,362 shares of the biopharmaceutical company’s stock valued at $7,468,000 after acquiring an additional 17,044 shares during the period. Legal & General Group Plc lifted its position in shares of SAGE Therapeutics by 3.7% during the 1st quarter. Legal & General Group Plc now owns 17,581 shares of the biopharmaceutical company’s stock valued at $2,831,000 after acquiring an additional 629 shares during the period. Principal Financial Group Inc. lifted its position in shares of SAGE Therapeutics by 3.2% during the 1st quarter. Principal Financial Group Inc. now owns 12,406 shares of the biopharmaceutical company’s stock valued at $1,998,000 after acquiring an additional 382 shares during the period. Allianz Asset Management GmbH lifted its position in shares of SAGE Therapeutics by 962.4% during the 1st quarter. Allianz Asset Management GmbH now owns 44,474 shares of the biopharmaceutical company’s stock valued at $7,163,000 after acquiring an additional 40,288 shares during the period. Finally, State of Alaska Department of Revenue acquired a new position in shares of SAGE Therapeutics during the 2nd quarter valued at $864,000.

About SAGE Therapeutics

Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. Its lead product candidate comprises brexanolone, a proprietary intravenous formulation of allopregnanolone that has completed III clinical trials for the treatment of post-partum depression (PPD).

Further Reading: Why is insider trading harmful?

Get a free copy of the Zacks research report on SAGE Therapeutics (SAGE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for SAGE Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.